On December 19, Qurient announced that it has decided to carry out a third-party paid-in capital increase of 6.26 million euros (approximately 10.9 billion KRW) for 'QLi5 Therapeutics,' a joint venture established with the Max Planck Institute in Germany and the Lead Discovery Center. With this investment, Qurient's stake in QLi5 will increase from approximately 58% to about 64%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
